Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo

被引:92
|
作者
Etemad-Moghadam, B
Sun, Y
Nicholson, EK
Fernandes, M
Liou, K
Gomila, R
Lee, J
Sodroski, J
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS,Dept Pathol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA
关键词
D O I
10.1128/JVI.74.9.4433-4440.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Changes in the envelope glycoprotein ectodomains of a nonpathogenic simian-human immunodeficiency virus (SHIV-89.6) that was serially passaged in vivo have been shown to be responsible for the increased pathogenicity of the resulting virus, SHIV-KB9 (G. B. Karlsson, et al., J. Exp. Med. 188:1159-1171, 1998). The 12 amino acid changes in the envelope glycoprotein ectodomains resulted in increased chemokine receptor-binding and syncytium-forming abilities. Here we identify the envelope glycoprotein determinants of these properties. A single amino acid change in the gp120 third variable (V3) loop was both necessary and sufficient for the observed increase in the binding of the SHIV-KB9 gp120 glycoprotein to the CCR5 chemokine receptor. The increased syncytium-forming ability of SHIV-KB9 involved, in addition to the V3 loop change, changes in the second conserved (C2) region of gp120 (residue 225) and in the gp41 ectodomain (residues 564 and 567). The C2 and gp41 ectodomain changes influenced syncytium formation in a cooperative manner. Changes in the V1/V2 gp120 variable loops exerted a negative effect on syncytium formation and chemokine receptor binding, supporting a previously described role of these changes in immune evasion. The definition of the passage-associated changes that determine the efficiency of chemokine receptor binding and membrane fusogenicity will allow evaluation of the contribution of these properties to in vivo CD4-positive lymphocyte depletion.
引用
收藏
页码:4433 / 4440
页数:8
相关论文
共 50 条
  • [1] Envelope glycoprotein determinants of increased entry in a pathogenic simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) passaged in monkeys
    Si, ZH
    Gorry, P
    Babcock, G
    Owens, CM
    Cayabyab, M
    Phan, N
    Sodroski, J
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2004, 20 (02) : 163 - 173
  • [2] Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo
    Etemad-Moghadam, B
    Sun, Y
    Nicholson, EK
    Karlsson, GB
    Schenten, D
    Sodroski, J
    JOURNAL OF VIROLOGY, 1999, 73 (10) : 8873 - 8879
  • [3] Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2)
    Cayabyab, M
    Karlsson, GB
    Etemad-Moghadam, BA
    Hofmann, W
    Steenbeke, T
    Halloran, M
    Fanton, JW
    Axthelm, MK
    Letvin, NL
    Sodroski, JG
    JOURNAL OF VIROLOGY, 1999, 73 (02) : 976 - 984
  • [4] Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys
    Si, ZH
    Cayabyab, M
    Sodroski, J
    JOURNAL OF VIROLOGY, 2001, 75 (09) : 4208 - 4218
  • [5] Envelope glycoproteins in a pathogenic Simian-Human Immunodeficiency Virus (SHIV-89.6P) determine the viral pathogenicity in pediatric SHIV infection of baboons
    Nganga, J.
    Imbuga, M.
    Gathuru, J.
    Otsyula, M.
    MOLECULAR & CELLULAR PROTEOMICS, 2004, 3 (10) : S43 - S43
  • [6] Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo
    Ye, YJ
    Si, ZH
    Moore, JP
    Sodroski, J
    JOURNAL OF VIROLOGY, 2000, 74 (24) : 11955 - 11962
  • [7] A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques
    Ten Haaft, P
    Verstrepen, B
    Überla, K
    Rosenwirth, B
    Heeney, J
    JOURNAL OF VIROLOGY, 1998, 72 (12) : 10281 - 10285
  • [8] Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)-infected nonhuman primates
    Di Mascio, Michele
    Paik, Chang H.
    Carrasquillo, Jorge A.
    Maeng, Jin-Soo
    Jang, Beom-Su
    Shin, In Soo
    Srinivasula, Sharat
    Byrum, Russ
    Neria, Achilles
    Kopp, William
    Catalfamo, Marta
    Nishimura, Yoshiaki
    Reimann, Keith
    Martin, Malcolm
    Lane, H. Clifford
    BLOOD, 2009, 114 (02) : 328 - 337
  • [9] Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys
    Etemad-Moghadam, B
    Karlsson, GB
    Halloran, M
    Sun, Y
    Schenten, D
    Fernandes, M
    Letvin, NL
    Sodroski, J
    JOURNAL OF VIROLOGY, 1998, 72 (10) : 8437 - 8445
  • [10] Impaired T-cell differentiation in the thymus at the early stages of acute pathogenic chimeric simian-human immunodeficiency virus (SHIV) infection in contrast to less pathogenic SHIV infection
    Motohara, Makiko
    Ibuki, Kentaro
    Miyake, Ariko
    Fukazawa, Yoshinori
    Inaba, Katsuhisa
    Suzuki, Hajime
    Masuda, Kyoko
    Minato, Nagahiro
    Kawamoto, Hiroshi
    Nakasone, Tadashi
    Honda, Mitsuo
    Hayami, Masanori
    Miura, Tomoyuki
    MICROBES AND INFECTION, 2006, 8 (06) : 1539 - 1549